Functional characterization of 22 novel CYP2D6 variants for the metabolism of Tamoxifen

被引:3
|
作者
Hu, Xiao-Xia [1 ]
Zhou, Quan [1 ]
Lan, Tian [1 ]
Huang, Xiang-Xin [1 ]
Liang, Bing-qing [1 ]
Dai, Da-Peng [2 ,3 ]
Cai, Jian-Ping [2 ,3 ]
Hu, Guo-Xin [1 ]
机构
[1] Wenzhou Med Univ, Sch Pharm, Dept Pharmacol, Wenzhou, Zhejiang, Peoples R China
[2] Beijing Hosp, Key Lab Geriatr, Beijing 100730, Peoples R China
[3] Minist Hlth, Beijing Inst Geriatr, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
allelic variants; CYP2D6; polymorphism; drug metabolism; tamoxifen; CYTOCHROME-P450; 2D6; GENETIC POLYMORPHISMS; CHINESE POPULATION; BREAST-CANCER; IN-VITRO; DEXTROMETHORPHAN; CONSEQUENCES; FREQUENCIES; ALLELE; WOMEN;
D O I
10.1111/jphp.12556
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives This study aimed to assess the catalytic characteristics of 24 CYP2D6 allelic isoforms found in Chinese Han population on the metabolism of tamoxifen in vitro. Methods Recombinant CYP2D6 microsomes of distinguished genotypes were used to characterize the corresponding enzyme activity towards tamoxifen. About 5-2500 mu M tamoxifen was incubated for 30 min at 37 degrees C. Using high-performance liquid chromatography to detect the products, the kinetic parameters Km, V-max and intrinsic clearance (V-max/K-m) of N-desmethyltamoxifen were determined. Key findings Of the 24 tested allelic variants, the differences of intrinsic clearance value were shown as follows: CYP2D6.89 was much higher than wild-type CYP2D6.1, 2 allelic isoforms (CYP2D6.88 and D336N) exhibited similar intrinsic clearance values as the wild-type enzyme, two variants displayed weak or no activity, while the rest 19 variants showed significantly reduced intrinsic clearance values ranging from 7.46 to 81.11%. Conclusion The comprehensive assessment of CYP2D6 variants provides significant insights into allele-specific activity towards tamoxifen in vitro, suggesting that most of the carriers of these alleles might be paid more attention when using CYP2D6-mediated drugs clinically.
引用
收藏
页码:819 / 825
页数:7
相关论文
共 50 条
  • [1] A novel CYP2D6 scoring system for the prediction of CYP2D6 activity: Application to tamoxifen metabolism.
    Borges, S.
    Li, L.
    Robarge, J.
    Nguyen, A.
    Azzouz, F.
    Desta, Z.
    Skaar, T.
    Flockhart, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S67 - S67
  • [2] Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine
    Xu, Ren-ai
    Gu, Er-min
    Zhou, Quan
    Yuan, Lingjing
    Hu, Xiaoxia
    Cai, Jianping
    Hu, Guoxin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 687 - 696
  • [3] Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism
    Ahmed, Nermin S.
    Elghazawy, Nehal H.
    ElHady, Ahmed K.
    Engel, Matthias
    Hartmann, Rolf W.
    Abadi, Ashraf H.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 112 : 171 - 179
  • [4] Functional characterization of CYP2D6 novel allelic variants identified in the Chinese Han population
    Xu, Qingqing
    Wu, Zhenqiang
    Yang, Lun
    Zhang, Xiaoqing
    Gai, Zhongtao
    Chen, Lili
    He, Lin
    Qin, Shengying
    PHARMACOGENOMICS, 2016, 17 (02) : 111 - 119
  • [5] Discovery and Enzyme Kinetic Characterization of Novel CYP2D6 Variants
    Zhong, Yun-shan
    Kong, Qi-hui
    Wang, Jing
    Ye, Feng
    Li, Xin-yue
    Zhang, Li-qun
    Dai, Da-peng
    Hu, Guo-xin
    Cai, Jian-ping
    Qian, Jian-chang
    Ji, Fu-sui
    CHEMICAL RESEARCH IN TOXICOLOGY, 2024, 37 (11) : 1903 - 1910
  • [6] CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance
    Higgins, Michaela J.
    Stearns, Vered
    CURRENT ONCOLOGY REPORTS, 2010, 12 (01) : 7 - 15
  • [7] CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance
    Michaela J. Higgins
    Vered Stearns
    Current Oncology Reports, 2010, 12 : 7 - 15
  • [8] Understanding CYP2D6 and Its Role in Tamoxifen Metabolism
    Smith, Edith Caroline
    ONCOLOGY NURSING FORUM, 2013, 40 (06) : 547 - 548
  • [9] FUNCTIONAL CHARACTERIZATION OF RARE CYP2D6 ALLELIC VARIANTS IN VIVO.
    Gaedigk, A.
    Twist, G. P.
    Miller, N. A.
    Farrow, E. G.
    Lowry, J. A.
    Soden, S. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S29 - S29
  • [10] Response to "Understanding CYP2D6 and Its Role in Tamoxifen Metabolism"
    Kaplan, Marcelle
    Mahon, Suzanne M.
    ONCOLOGY NURSING FORUM, 2014, 41 (01) : 12 - 12